$AGIO
AGIOS PHARMACEUTICALS, INC.

2017 Q2 Form 10-Q Financial Statement

#000119312517157874 Filed on May 04, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2017 Q1 2016 Q4
Revenue $11.35M $10.51M $22.65M
YoY Change 62.6% -66.41% 264.23%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.13M $14.82M $15.38M
YoY Change 27.61% 36.72% 51.08%
% of Gross Profit
Research & Development $79.82M $62.73M $64.68M
YoY Change 57.11% 42.45% 75.14%
% of Gross Profit
Depreciation & Amortization $1.600M $1.591M $1.700M
YoY Change 14.29% 27.69% 54.55%
% of Gross Profit
Operating Expenses $95.95M $77.56M $80.06M
YoY Change 51.22% 41.33% 69.91%
Operating Profit -$84.60M -$67.05M -$57.41M
YoY Change 49.81% 184.17% 40.37%
Interest Expense $1.520M $880.0K $920.0K
YoY Change 192.31% 120.0% 228.57%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$83.08M -$66.17M -$56.49M
YoY Change 48.49% 185.22% 39.07%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$83.08M -$66.17M -$23.20M
YoY Change 48.49% 185.22% -42.89%
Net Earnings / Revenue -732.26% -629.67% -102.43%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.777M -$1.565M -$1.341M
COMMON SHARES
Basic Shares Outstanding 48.20M shares 42.23M shares 42.01M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q2 2017 Q1 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $586.0M $479.8M $541.3M
YoY Change 25.92% 53.34% 70.76%
Cash & Equivalents $138.7M $200.3M $160.8M
Short-Term Investments $447.3M $279.5M $380.6M
Other Short-Term Assets $13.00M $12.40M $10.30M
YoY Change 46.07% 34.78% 18.39%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $604.7M $506.9M $559.9M
YoY Change 24.89% 53.84% 65.98%
LONG-TERM ASSETS
Property, Plant & Equipment $24.77M $24.14M $25.34M
YoY Change -1.44% 5.18% 9.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $129.9M $23.40M $32.30M
YoY Change 176.97% -45.45% -45.16%
Other Assets $1.249M $2.888M $1.615M
YoY Change -9.62% 244.63% 164.32%
Total Long-Term Assets $155.9M $50.45M $59.20M
YoY Change 112.3% -24.3% -28.44%
TOTAL ASSETS
Total Short-Term Assets $604.7M $506.9M $559.9M
Total Long-Term Assets $155.9M $50.45M $59.20M
Total Assets $760.6M $557.3M $619.1M
YoY Change 36.41% 40.69% 47.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $23.41M $16.15M $17.11M
YoY Change 26.89% 17.5% 15.99%
Accrued Expenses $29.64M $25.11M $32.00M
YoY Change 105.64% 105.06% 100.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $93.65M $82.43M $88.43M
YoY Change 39.22% 82.95% 67.21%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $158.0M $167.5M $172.1M
YoY Change -21.51% 795.72% 678.73%
Total Long-Term Liabilities $158.0M $167.5M $172.1M
YoY Change -21.51% 795.72% 678.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $93.65M $82.43M $88.43M
Total Long-Term Liabilities $158.0M $167.5M $172.1M
Total Liabilities $251.6M $249.9M $260.5M
YoY Change -6.29% 292.31% 247.8%
SHAREHOLDERS EQUITY
Retained Earnings -$632.6M -$549.6M -$483.2M
YoY Change 73.88% 78.5% 69.72%
Common Stock $1.142B $857.1M $842.1M
YoY Change 75.03% 33.9% 33.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $509.0M $307.4M $358.6M
YoY Change
Total Liabilities & Shareholders Equity $760.6M $557.3M $619.1M
YoY Change 36.41% 40.69% 47.38%

Cashflow Statement

Concept 2017 Q2 2017 Q1 2016 Q4
OPERATING ACTIVITIES
Net Income -$83.08M -$66.17M -$23.20M
YoY Change 48.49% 185.22% -42.89%
Depreciation, Depletion And Amortization $1.600M $1.591M $1.700M
YoY Change 14.29% 27.69% 54.55%
Cash From Operating Activities -$59.00M -$74.07M -$51.20M
YoY Change -137.39% 289.86% 67.87%
INVESTING ACTIVITIES
Capital Expenditures -$1.000M $293.0K -$1.200M
YoY Change -64.29% -88.43% -45.45%
Acquisitions
YoY Change
Other Investing Activities -$274.6M $109.8M -$76.30M
YoY Change -813.25% -992.68% -428.88%
Cash From Investing Activities -$275.8M $109.6M -$77.60M
YoY Change -872.55% -840.22% -471.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $270.2M $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 273.2M $4.046M 4.000M
YoY Change 18113.33% 267.82% 207.69%
NET CHANGE
Cash From Operating Activities -59.00M -$74.07M -51.20M
Cash From Investing Activities -275.8M $109.6M -77.60M
Cash From Financing Activities 273.2M $4.046M 4.000M
Net Change In Cash -61.60M $39.52M -124.8M
YoY Change -131.59% -220.87% 1403.61%
FREE CASH FLOW
Cash From Operating Activities -$59.00M -$74.07M -$51.20M
Capital Expenditures -$1.000M $293.0K -$1.200M
Free Cash Flow -$58.00M -$74.37M -$50.00M
YoY Change -136.11% 245.36% 76.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48204878 shares
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39035000
CY2016Q1 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5285000
CY2017Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
198648000
CY2017Q1 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
23423000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42382901 shares
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42382901 shares
CY2017Q1 us-gaap Assets
Assets
557316000
CY2017Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
16911000
CY2017Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
3473000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
506866000
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
857107000
CY2017Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
241800000
CY2017Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
279480000
CY2017Q1 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
123 Securities
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200278000
CY2017Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2017Q1 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
3452000
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
42000
CY2017Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
150596000
CY2017Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2017Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
16152000
CY2017Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
37690000
CY2017Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5060000
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-212000
CY2017Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
11265000
CY2017Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2017Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2017Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25114000
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
557316000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
82429000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1295000
CY2017Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2888000
CY2017Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24139000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2909093 shares
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-549557000
CY2017Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12391000
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
37.76
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
307380000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
47.70
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6129794 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
47.70
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6129794 shares
CY2017Q1 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
13474000
CY2017Q1 agio Cash Equivalents And Available For Sale Securities
CashEquivalentsAndAvailableForSaleSecurities
501551000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71764000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11092000
CY2016Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
32250000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42220444 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42220444 shares
CY2016Q4 us-gaap Assets
Assets
619094000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
17773000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
3412000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
559892000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000 shares
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
842013000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
335400000
CY2016Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
380560000
CY2016Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear
158 Securities
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
160754000
CY2016Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
3428000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
42000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
154297000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17106000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
35913000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
476000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-313000
CY2016Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
4886000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
32002000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
619094000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
88433000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
168000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1615000
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25337000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
358591000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
46.79
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-483151000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10264000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5218880 shares
CY2016Q4 agio Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
20266000
CY2016 agio Available For Sale Securities Non Current Minimum Liquidating Period
AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod
P12M
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-163000
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
AGIOS PHARMACEUTICALS INC
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6262177 shares
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001439222
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
39524000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.56
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10734000
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
213000
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14823000
CY2017Q1 us-gaap Depreciation
Depreciation
1591000
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66065000
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2017Q1 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
801000
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
136585000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6889000
CY2017Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4146000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
77555000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-66166000
CY2017Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
6379000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
109552000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-994000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3425000
CY2017Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-40000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-67047000
CY2017Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
26740000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4046000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
101000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1924000
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
881000
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-74074000
CY2017Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
24000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
293000
CY2017Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
142539 shares
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
49.85
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
66.24
CY2017Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
21.56
CY2017Q1 dei Trading Symbol
TradingSymbol
AGIO
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62732000
CY2017Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
100000
CY2016Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
198868000
CY2016Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2902000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1129352 shares
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
75899 shares
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10734000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42280525 shares
CY2017Q1 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
0.0
CY2017Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
10508000
CY2017Q1 agio Available For Sale Securities Non Current Minimum Liquidating Period
AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod
P12M
CY2017Q1 agio Proceeds From Stock Options Exercised In Other Current Assets
ProceedsFromStockOptionsExercisedInOtherCurrentAssets
6000
CY2017Q1 agio Public Offering Costs In Other Current Assets
PublicOfferingCostsInOtherCurrentAssets
329000
CY2016Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-126000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5396377 shares
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-32729000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.61
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9107000
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
607000
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10837000
CY2016Q1 us-gaap Depreciation
Depreciation
1246000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-23198000
CY2016Q1 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
560000
CY2016Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1108000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
54875000
CY2016Q1 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-1411000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-14828000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-293000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
857000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-23594000
CY2016Q1 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
211163000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1108000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-5892000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
396000
CY2016Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-19009000
CY2016Q1 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-2803000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2533000
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44038000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
9107000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37864084 shares
CY2016Q1 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
25000000
CY2016Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
31281000
CY2016Q1 agio Proceeds From Stock Options Exercised In Other Current Assets
ProceedsFromStockOptionsExercisedInOtherCurrentAssets
17000
CY2016Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22791000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-23198000
CY2016Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
407000

Files In Submission

Name View Source Status
0001193125-17-157874-index-headers.html Edgar Link pending
0001193125-17-157874-index.html Edgar Link pending
0001193125-17-157874.txt Edgar Link pending
0001193125-17-157874-xbrl.zip Edgar Link pending
agio-20170331.xml Edgar Link completed
agio-20170331.xsd Edgar Link pending
agio-20170331_cal.xml Edgar Link unprocessable
agio-20170331_def.xml Edgar Link unprocessable
agio-20170331_lab.xml Edgar Link unprocessable
agio-20170331_pre.xml Edgar Link unprocessable
d368298d10q.htm Edgar Link pending
d368298dex311.htm Edgar Link pending
d368298dex312.htm Edgar Link pending
d368298dex321.htm Edgar Link pending
d368298dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending